March 7, 2017
CancerLinQ® is a big data project aimed at rapidly improving the overall quality of cancer care. Since its origins, the project has come to fruition in part through support provided by the generous donors of the Conquer Cancer Foundation of ASCO.
CancerLinQ® will unlock real-world patient data from millions of electronic medical records, and securely process and analyze the data to provide immediate quality feedback and personalized insights to physicians on a scope that was previously unattainable.
The system went live in February 2016 and has successfully connected with most major EHR systems, including both enterprise and oncology-specific systems, showing data can be shared seamlessly and securely across technical platforms.
The generous donors to CancerLinQ to date have helped make these advancements possible.
Donors to CancerLinQ join a coalition of patients, partners, providers and supporters committed to improving cancer care the lives of cancer patients through innovation and change.
CancerLinQ is supported in part through the Conquer Cancer Foundation. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ® is a project of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org.